In light of the high prevalence of patients infected with both HIV and M. tuberculosis our findings indicate that therapeutic targeting of IDO-1 should not increase the risk of exacerbating tuberculosis in HIV patients. This evidence concerns the gene IDO1 and tuberculosis.